Samantha et al [36] showed that Jak2 is an important target in CML, and the Jak inhibitor AG490 was able to induce apoptosis in cells that expressed imatinib-resistant mutants of Bcr/Abl. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.